LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

Home・Akcijų sąrašas・CytomX Therapeutics Inc

CytomX Therapeutics Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

3.23 2.87

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

3.13

Max

3.3

Pagrindiniai rodikliai
By Trading Economics
Pajamos	8.3M -18M
Pardavimai	9.6M 10M
P/E Sektoriaus vid.	22.5 50.102
Pelnas, tenkantis vienai akcijai	-0.1
Pelno marža	-177.89
Darbuotojai	69
EBITDA	8M -19M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+289.24% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-06

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-107M 803M
Ankstesnė atidarymo kaina	0.36
Ankstesnė uždarymo kaina	3.23

Naujienos nuotaikos

By Acuity

100%

316 / 344 reitingas Healthcare

CytomX Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-06-02 20:30; UTC

Uždarbis

Palo Alto Networks 3Q Revenue Rises as Customers Beef Up Cyber Defenses

2026-06-02 23:58; UTC

Rinkos pokalbiai

Australia's Consumer Sector Expected to Be Stung by Housing Downturn -- Market Talk

2026-06-02 23:46; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-06-02 23:46; UTC

Rinkos pokalbiai

Nikkei May Rise as AI Demand Hopes Continue -- Market Talk

2026-06-02 23:41; UTC

Rinkos pokalbiai

Oil Rises Amid Signs of U.S.-Iran Peace Talks Stalling -- Market Talk

2026-06-02 23:01; UTC

Įsigijimai, susijungimai, perėmimai

ACCC Says Owner of Metro Petroleum Brand to Buy the 41 Sites

2026-06-02 23:01; UTC

Įsigijimai, susijungimai, perėmimai

ACCC Says Ampol Must Sell 41 Retail Fuel Sites to an Approved Purchaser

2026-06-02 23:00; UTC

Įsigijimai, susijungimai, perėmimai

Australia's Competition Regulator Approves Ampol's Purchase of EG Australia With Conditions

2026-06-02 22:57; UTC

Rinkos pokalbiai

Australian Dollar Could Fall Following 1Q GDP Data -- Market Talk

2026-06-02 22:50; UTC

Rinkos pokalbiai

Ulta Beauty Says TikTok Shop Will Provide 'Halo' Effect -- Market Talk

2026-06-02 21:07; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-06-02 21:07; UTC

Rinkos pokalbiai

Tokenized Assets Need Access to Digital-Finance Plumbing -- Market Talk

2026-06-02 21:00; UTC

Uždarbis

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2026-06-02 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-06-02 20:46; UTC

Uždarbis

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2026-06-02 20:38; UTC

Uždarbis

GitLab Stock Rises as the Software Company Raises Guidance on AI Business Momentum -- Barrons.com

2026-06-02 20:21; UTC

Uždarbis

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2026-06-02 20:12; UTC

Uždarbis

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2026-06-02 20:05; UTC

Uždarbis

Palo Alto Networks 3Q Product Rev $594M

2026-06-02 20:05; UTC

Uždarbis

Palo Alto Networks Sees FY26 Next-Generation Security ARR $8.9B-$8.95B

2026-06-02 20:05; UTC

Uždarbis

Palo Alto Networks Raises FY26 View To Adj EPS $3.77-Adj EPS $3.79 >PANW

2026-06-02 20:05; UTC

Uždarbis

Palo Alto Networks 3Q Subscription and Support Rev $2.41B

2026-06-02 20:05; UTC

Uždarbis

Palo Alto Networks Sees FY26 Remaining Performance Obligation $20.9B-$21B

2026-06-02 20:05; UTC

Uždarbis

Palo Alto Networks Sees 4Q Rev $3.345B-$3.355B >PANW

2026-06-02 20:05; UTC

Uždarbis

Palo Alto Networks Sees 4Q Adj EPS 96c-Adj EPS 98c >PANW

2026-06-02 20:05; UTC

Uždarbis

Palo Alto Networks on Track to Achieve 40% Adj Free Cash Flow Margin in FY28

2026-06-02 20:05; UTC

Uždarbis

Palo Alto Networks Raises FY26 View To Rev $11.415B-$11.425B >PANW

2026-06-02 20:05; UTC

Uždarbis

Palo Alto Networks 3Q Remaining Performance Obligation $18.4B

2026-06-02 20:05; UTC

Uždarbis

Palo Alto Networks 3Q Adj EPS 85c >PANW

2026-06-02 20:05; UTC

Uždarbis

Palo Alto Networks 3Q Loss $177M >PANW

Akcijų palyginimas

Kainos pokytis

CytomX Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

289.24% į viršų

12 mėnesių prognozė

Vidutinis 12.3 USD 289.24%

Aukščiausias 16 USD

Žemiausias 6 USD

Remiantis 10 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines CytomX Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

10 ratings

Pirkti

Laikyti

Parduoti

Remiantis 10 analitikų, pateikusių CytomX Therapeutics Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

316 / 344 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę CytomX Therapeutics Inc

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.